Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CTSA | P10619 | 1/20 | 0.30 |
| ▸ | BACE1 | P56817 | 1/20 | 0.30 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24984631 | 1.00 | POLB (0.34) | POLBGABRA5MEN1HPGDKMT2A | |
| SCHEMBL24986046 | 0.94 | POLB (0.33) | POLBMEN1HPGDKMT2ALMNA | |
| SCHEMBL24986045 | 0.94 | POLB (0.33) | POLBMEN1HPGDKMT2ALMNA | |
| SCHEMBL24986770 | 0.94 | POLB (0.37) | POLBGABRA5MEN1HPGDKMT2A | |
| SCHEMBL23904759 | 0.93 | GABRA5 (0.32) | GABRA5 | |
| SCHEMBL24984978 | 0.93 | GABRA5 (0.32) | GABRA5 | |
| SCHEMBL24984979 | 0.93 | GABRA5 (0.32) | GABRA5 | |
| SCHEMBL23905712 | 0.92 | POLB (0.35) | POLBMEN1HPGDKMT2ALMNA | |
| SCHEMBL23905267 | 0.92 | POLB (0.35) | POLBMEN1HPGDKMT2ALMNA | |
| SCHEMBL25116822 | 0.90 | GABRA5 (0.34) | GABRA5BACE1BACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230125803-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | ENANTA PHARM INC (US) | 2023-04-27 | — | — | US | disclosed |
| US-11572367-B2 | Antiviral heterocyclic compounds | ENANTA PHARMACEUTICALS, INC. (US) | 2023-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11572367-B2 | Antiviral heterocyclic compounds | ACE, HPRT1, ACE2 | POLB 2743/4885GABRA5 3773/4885MEN1 1038/4885 |
| US-20230125803-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | ACE, HPRT1, ACE2 | POLB 2743/4885GABRA5 3773/4885MEN1 1038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.